Tien-Hao Lee, MD
Endocrinology, Diabetes & Metabolism · Saint Petersburg, FLNPI 1356872618
Payments from drug & device makers
Across 362 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$618
- Lilly USA, LLC$611
- Bayer$599
- Amgen$544
- Boehringer Ingelheim$450
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $1,465 |
| AbbVie | 26 | $618 |
| Lilly USA, LLC | 38 | $611 |
| Bayer | 21 | $599 |
| Amgen(2 entities) | 25 | $544 |
| Boehringer Ingelheim | 22 | $450 |
| Sanofi-aventis U.S. LLC | 17 | $430 |
| Abbott | 19 | $392 |
| Amneal Pharmaceuticals LLC | 15 | $312 |
| AstraZeneca(2 entities) | 11 | $280 |
| Insulet Corporation | 3 | $268 |
| Novartis | 9 | $250 |
| Recordati_rare_diseases_inc. | 9 | $234 |
| Dexcom, Inc. | 10 | $210 |
| Medtronic | 3 | $208 |
| Corcept Therapeutics | 8 | $171 |
| BETA Bionics, Inc. | 7 | $146 |
| Xeris Pharmaceuticals, Inc. | 7 | $139 |
| Radius Health, Inc. | 6 | $124 |
| Kyowa Kirin, Inc. | 5 | $118 |
| Pfizer | 5 | $112 |
| Neurocrine Biosciences, Inc. | 3 | $88 |
| IBSA Pharma Inc. | 4 | $82 |
| Antares Pharma, Inc. | 4 | $79 |
| Cequr Corporation | 2 | $58 |
| Mannkind Corporation | 2 | $46 |
| Sequel Med Tech, LLC | 2 | $42 |
| Merck | 2 | $37 |
| Renalytix AI, Inc. | 2 | $36 |
| Verity Pharmaceuticals Inc. | 1 | $27 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Averitas Pharma Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Tolmar, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$239
- MINIMED 780G$145
- Kerendia$127
- Ozempic$118
- EVENITY$114
How this compares
$8,284 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 220 | $240,047 |
| JardianceEmpagliflozin | 108 | $121,055 |
| TrulicityDulaglutide | 92 | $107,748 |
| MounjaroTirzepatide | 85 | $96,327 |
| FarxigaDapagliflozin Propanediol | 58 | $67,450 |
| RybelsusSemaglutide | 43 | $48,146 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $32,143 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $26,965 |
| TradjentaLinagliptin | 29 | $17,197 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $15,949 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $15,675 |
| JanuviaSitagliptin Phosphate | 12 | $15,422 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $11,325 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $11,081 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,465 | $288,192263 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30 | $611 | $204,898188 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $450 | $145,852148 claims |
| AstraZenecaFarxiga | $280 | $67,45058 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $430 | $32,14329 claims |
| MerckJanuvia | $37 | $15,42212 claims |
| AbbVieSynthroid | $618 | $5,15349 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $312 | $4,794308 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Saint Petersburg
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.